Follow the 케이바이오랩스 share price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 케이바이오랩스 has published 38 insider filings. Market capitalisation: €21.2bn. The latest transaction was filed on 16 March 2026 (Other). Among the most active insiders: 미래아이앤지. All data is free.
38
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
22 ops.
Sell Volume
2Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 19,127 of 26,063 companies
36.0
score / 100
Value
55
Quality
18
FCF yld41%
Earn yld-16%
EV/EBITDA·
ROE·
Gross mgn14%
Net mgn-3.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.